Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Systematic review and meta-analysis were performed to examine the efficacy and safety of MCs treatment among children.

Safety

Cannabis Law Report

JULY 28, 2021

Cepharanthine is on its way to establishing itself as a once per day, oral anti-cancer therapeutic with a well-established safety profile which will pave the way for an expedited clinical development pathway and future partnering opportunities with pharmaceutical companies. 2017 Nov 27;8(67):111144-111160. Epub 2017 Aug 4.

Research and Development

Project CBD

FEBRUARY 28, 2023

CBD first appeared on the natural channel’s top 40 list in 2017, ranking 12th, after sales growth of more than 300% from the previous year. million more on CBD products in 2021 compared to 2017 — a 413.4% Despite its top rank in 2021, sales of this ingredient have slowed in recent years. Consumers spent roughly $31.3

CBD

The Cannigma

AUGUST 31, 2021

The researchers stated that these knowledge gaps must be addressed and that “clinical trial data about how medical cannabis improves patient quality of life domains is desperately needed as this information can impact clinical decision-making.”.

Education

LifeCannMD

AUGUST 2, 2024

More clinical trials are needed to establish definitive efficacy and safety profiles. 2017 Study Published in “Cannabis and Cannabinoid Research” – Findings: This study found that medical cannabis users experienced significant reductions in headache and migraine frequency. .

Clinical Trials

Cannabis Law Report

JULY 9, 2021

Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , Clinical Trial ID NCT03866174, available at [link].

Law

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer.

Clinical Trials

Cannabis Law Report

JULY 1, 2021

Clinical trials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency identified psilocybin as a breakthrough for treatment-resistant depression. The Project.

Law

Peninsula Alternative Health

MAY 15, 2019

The joint study conducted by Ben Gurion University and Soroka Medical Center in Beersheba analyzed 188 teens diagnosed with Autistic Spectrum Disorder (ASD) between 2015 and 2017. 2017) The current status of artisanal cannabis for the treatment of epilepsy in the United States. tetrahydrocannabinol (THC). improvement in good sleep.

Conditions

Healer

DECEMBER 17, 2021

The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. The Journal of Clinical Pharmacology 60.4 2017): 1586-1592. 2020): 432-438. Gaston, Tyler E., Epilepsia 58.9

CBD

TheAnswerPage

JANUARY 11, 2022

For example, most, if not all, states have legalized the use of medical marijuana to treat specific health conditions for which there is no or only poor quality clinical evidence of efficacy and safety. to take a medical marijuana course that reviews the endocannabinoid system and the therapeutic use of marijuana.

Patients

Cannabis Law Report

JANUARY 11, 2019

However, we firmly disagree that the referenced clinical trials are in fact “substantial,” as the trials were extremely limited in scope, and funding and the publication of these trials were limited. CBD has been found to be generally well tolerated with a good safety profile.”.

Hemp

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. 2018 ; Månsson 2016 , 2017 ; Abalo 2019a , 2019b ; Paimre 2017 ). 2015 ; Kaiser 2011 ; Mortensen et al.

Research and Development

Cannabis Law Report

SEPTEMBER 3, 2019

Andrew Cormack, Head of Production , brings considerable senior experience from GMP pharmaceutical, nutraceutical and food companies, having managed product launches, facility buildouts and large workforces to achieve quality, cost and safety targets. MediPharm Labs Australia was established in 2017. Telephone: 705-719-7425 ext 216.

Pharmaceutical

Healer

DECEMBER 17, 2021

The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. The Journal of Clinical Pharmacology 60.4 2017): 1586-1592. [7] 2020): 432-438. [6] 6] Gaston, Tyler E.,

CBD

Cannabis Law Report

JUNE 11, 2019

Given the controversy over the efficacy and safety of cannabis for therapeutic purposes, a key question in these cases, is whether cannabis meets the requirement of medical justification. Ahn , 2016 BCSC 795, reversed on other grounds 2017 BCCA 221. Mistry , 2017 BCSC 239. Tower , 2017 BCSC 2068. Tower , 2017 BCSC 2068.

Chronic Pain

Cannabis Law Report

OCTOBER 29, 2019

ElleVet Sciences is pleased to announce the results and publication of the first safety study on the use of hemp CBD/CBDA. The 12-week safety study, conducted by Dr. Joseph Wakshlag, DVM, Ph.D., The clinical trial results confirmed more than 80% of dogs showed significant or dramatic improvement. Wakshlag, DVM, Ph.D.,

Safety

The Cannigma

OCTOBER 19, 2021

A clinical trial published in 2015 found that the test subjects had “significantly higher blood THC” levels when they used cannabis along with alcohol, and combining the two led to increased performance impairment. CBD and alcohol safety.

Research and Development

Canna Law Blog

APRIL 17, 2020

When it comes to CBD the, research is limited but a small clinical trial at Colorado State University found that CBD oil reduced seizures in epileptic dogs meaning that it may have similar effects as found in humans. — Teddy McDermott (@MayorTomCanine) December 14, 2017. What’s going on here in Indiana?

Pets

Cannabis Law Report

MAY 29, 2022

To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision. In 2017, FDA granted a request for Breakthrough Therapy designation for MDMA to treat PTSD.

Research and Development

Alchimia

FEBRUARY 1, 2022

To date, there are several studies that have tried to verify the safety and toxicology of CBD when it is administered to treat certain diseases. Some of the participants in such studies, such as the one conducted to determine the safety and effectiveness of CBD in treating epilepsy , reported the following side effects: Diarrhea.

CBD

Canna Law Blog

MARCH 4, 2020

Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). Recently, the decriminalization of psilocybin (by various cities) has been in the news as an emerging medicine.

Legalization

The Cannigma

MARCH 12, 2021

We’re not going to get over the fact that there’s not the same sort of clinical trial and that type of evidence for cannabis and cannabis treatments in the very near future for various reasons. And in my belief, it should be cannabis, because of the safety profile, number one.

Legalization

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. In 2017, the FDA designated MDMA a breakthrough therapy for PTSD.

Research and Development

Cannabis Law Report

OCTOBER 17, 2019

Many experts believe it can lead to beneficial treatments, reiterated in a report released by the National Academies of Sciences, Engineering, and Medicine in January 2017. Many of these are meant to address public safety risks, especially for young people. Both THC and CBD are psychoactive, but unlike THC, CBD does not intoxicate.

Law

NORML

JANUARY 28, 2019

The National Center for Biotechnology Information has summarized a group of FDA approved randomized clinical trials, finding evidence for cannabis as medicine. National Library of Medicine has more than 26,000 published studies/reviews across 24 databases regarding cannabis available to read online.

Data